Cargando…
Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
Recently several studies have demonstrated the implications of mutations in DNA damage response (DDR) pathways for immune checkpoint blockade (ICB) treatment. However, smaller sample sizes, lesser cancer types, and the lack of multivariate-adjusted analyses may produce unreliable results. From the M...
Autores principales: | Zhang, Wenjing, Zhang, Liwen, Jiang, Hao, Li, Yuting, Wang, Suzhen, Wang, Qinghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610133/ https://www.ncbi.nlm.nih.gov/pubmed/34747718 http://dx.doi.org/10.18632/aging.203670 |
Ejemplares similares
-
Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
por: Sun, Shangqin, et al.
Publicado: (2021) -
Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021) -
Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma
por: Wang, Qinghua, et al.
Publicado: (2021) -
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020) -
Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)